Hiroshi Uchino
13PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (13)
Sort by Publication Date:
|Apr 08, 2026
Real-World Effectiveness and Safety of Escalating Once-Weekly Semaglutide from 0.5 to 1.0 mg in Type 2 Diabetes.Genki Sato, Hiroshi Uchino, Kota Takuma
|Nov 17, 2025
Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes: A Retrospective Observational Multicenter Study (ORIGAMI Study).Yoko Iwata, Fukumi Yoshikawa, Manabu Saito
|Jun 25, 2025
Impact of baseline alanine aminotransferase levels on the efficacy of dapagliflozin and sitagliptin: Latent class analysis from the DIVERSITY-CVR study.Kohei Mochizuki, Ayako Fuchigami, Takahisa Hirose
|May 09, 2025
Hypoglycemic timeslots after hospital discharge in patients with diabetes on multiple daily insulin injection: Dose of Insulin CHanged According to the Reported Glucose by Libre Pro (DISCHARGe study).Manabu Saito, Hiroshi Uchino, Ayako Fuchigami
|Jan 14, 2025
Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study.Atsushi Itsukaichi, Fukumi Yoshikawa, Ayako Fuchigami
|Aug 07, 2024
Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study.Genki Sato, Hiroshi Uchino, Takahisa Hirose
Pageof 3
